This company operates a high-throughput in vivo (HTV) discovery engine that combines massively multiplexed in vivo screening with AI-powered design. The engine sculpts pharmacokinetics and biodistribution properties of biologics directly within living systems to solve tissue-specific delivery challenges. Manifold Bio develops targeted medicines, including modular shuttles, optimized in vivo for precise payload delivery across various tissues.
Funding
$77.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Delivering therapeutic modalities across the blood-brain barrier and to specific brain regions remains a significant challenge, limiting the efficacy of treatments for neurological disorders. Traditional methods lack the throughput necessary to efficiently evaluate the distribution and efficacy of diverse protein designs in vivo.
Solution
Manifold Bio is developing mCodes, a protein barcoding platform that enables high-throughput, in vivo multiplexing to evaluate the distribution of up to 100 protein designs simultaneously within a single animal. This technology facilitates the development of targeted biologics for neurological disorders by allowing for rapid screening and optimization of protein therapeutics. mCodes are specific, sensitive, inert, and quantitative, serving as unique identifiers to track and quantitate large pools of biotherapeutic drug candidates in complex living systems. The platform leverages AI-guided protein design and a growing portfolio of tissue-specific shuttles to enhance therapeutic delivery.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel targeted therapies for neurological disorders and other diseases requiring enhanced therapeutic delivery.
Features
- mCodes: Protein barcoding and quantitation technology for in vivo screening.
- AI-Guided Protein Design: Generative design of libraries and antibodies combined with high-throughput display.
- In Vivo Multiplexing: Evaluate distribution of 100 protein designs simultaneously in a single animal.
- Brain shuttles optimized for crossing the blood-brain barrier.
- Emerging shuttles for other tissue types, expanding therapeutic reach.
- Shuttled Antibody therapeutics for Alzheimer's Disease, Parkinson's Disease / MSA, and Multiple Sclerosis.